NCT05817422View on ClinicalTrials.gov

Monovalent Chimpanzee Adenoviral-Vectored Marburg Virus Vaccine in Healthy Adults

PHASE2CompletedINTERVENTIONAL

Enrollment

126

Participants

Timeline

Start Date

October 19, 2023

Primary Completion Date

April 25, 2025

Study Completion Date

April 25, 2025

Conditions

Marburg Virus Disease

Interventions

BIOLOGICAL

cAd3-Marburg vaccine

The recombinant chimpanzee adenovirus Type 3-vectored Marburg vaccine, (cAd3-Marburg) is composed of a cAd3 vector that expresses Marburg wild type glycoprotein (WT GP) from the Angola strain.

OTHER

Placebo

0.9% NaCl solution for injection.

Trial Locations (2)

Unknown

KEMRI/Centre for Respiratory Diseases Research Siaya Clinical Research Annex, Siaya

Makerere University-Walter Reed Project, Kampala

All Listed Sponsors

collaborator

Biomedical Advanced Research and Development Authority

FED

lead

Albert B. Sabin Vaccine Institute

OTHER

NCT05817422 - Monovalent Chimpanzee Adenoviral-Vectored Marburg Virus Vaccine in Healthy Adults | Biotech Hunter | Biotech Hunter